Peel Hunt reiterated their add rating on shares of Abcam (LON:ABC) in a report published on Thursday morning, ThisIsMoney.Co.Uk reports.
A number of other equities analysts have also commented on the company. Liberum Capital reaffirmed a hold rating and issued a GBX 1,230 ($16.07) price objective on shares of Abcam in a research note on Monday, November 11th. JPMorgan Chase & Co. decreased their target price on shares of Abcam from GBX 1,144 ($14.95) to GBX 1,134 ($14.82) and set a neutral rating for the company in a research report on Monday, September 16th. Royal Bank of Canada restated a sector performer rating and set a GBX 1,300 ($16.99) price target on shares of Abcam in a report on Tuesday, November 12th. Finally, Berenberg Bank restated a buy rating and set a GBX 1,330 ($17.38) price target on shares of Abcam in a report on Monday, September 9th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of GBX 1,272.33 ($16.63).
Shares of ABC stock opened at GBX 1,374 ($17.95) on Thursday. Abcam has a 1-year low of GBX 1,006 ($13.15) and a 1-year high of GBX 1,523 ($19.90). The stock has a market cap of $2.83 billion and a price-to-earnings ratio of 63.03. The stock has a 50-day moving average of GBX 1,242.92 and a 200-day moving average of GBX 1,280.92.
Abcam Company Profile
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
Further Reading: What is a recession?
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.